Abstract
Clinical trials have demonstrated the safety and efficacy of autologous endothelial progenitor cell (EPC) therapy in various diseases. Since EPCs’ functions are influenced by genetic, systemic and environmental factors, the therapeutic potential of each individual EPCs is unknown and may affect treatment outcome. Therefore, our aim was to compare EPCs function among healthy donors in order to predict blood vessel formation (angiogenesis) before autologous EPC transplantation. Human EPCs were isolated from the blood of ten volunteers. EPCs proliferation rate, chemoattractant ability, and CXCR4 mRNA levels were different among donors (p < 0.0001, p < 0.01, p < 0.001, respectively). A positive correlation was found between SDF-1, CXCR4, and EPCs proliferation (R = 0.736, p < 0.05 and R = 0.8, p < 0.01, respectively). In-vivo, blood vessels were counted ten days after EPCs transplantation in a subcutaneous mouse model. Mean vessel density was different among donors (p = 0.0001); nevertheless, donors with the lowest vessel densities were higher compared to control (p < 0.05). Finally, using a linear regression model, a mathematical equation was generated to predict blood vessel density relying on: (i) EPCs chemoattractivity, and (ii) VEGFR-2 mRNA levels. Results reveal differences in EPCs functions among healthy individuals, emphasizing the need for a potency assay to pave the way for standardized research and clinical use of human EPCs.
Highlights
In the last decade, there has been growing interest in clinical research using autologous transplantation of endothelial progenitor cells (EPCs) as a new strategy to achieve therapeutic angiogenesis in humans
In order to compare the phenotype, genotype, and function of each individual patient’s EPCs, blood was drawn from 18 unrelated healthy donors who signed an informed consent
mesenchymal stem cells (MSCs), we investigated the chemotactic ability of EPC Conditioned Medium (EPC-CM) to enhance MSCs migration in a Boyden chamber migration assay
Summary
There has been growing interest in clinical research using autologous transplantation of endothelial progenitor cells (EPCs) as a new strategy to achieve therapeutic angiogenesis in humans. Safety and efficacy of autologous EPC therapy has been demonstrated in clinical studies of infarcted myocardium in humans [1,2,3,4,5]. The clinical use of autologous EPCs transplantation was described in many medical fields including: acute cerebral infarct [6] diabetic foot [7], critical limb ischemia [8], liver cirrhosis [9] and traumatic bone defects [10]. Angiogenesis is important to maintain the integrity of tissue perfusion, which is crucial for physiologic organ function. The reduction and dysfunction of circulating EPCs have been reported in both type I
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
